Gomathy Baskar | Breast Cancer | Best Researcher Award

Published on by NESIN Awards

Assist. Prof. Dr. Gomathy Baskar | Breast Cancer | Best Researcher Award

Assistant Professor | Saveetha Institute of Medical and Technical Sciences | India

Assist. Prof. Dr. Gomathy Baskar, M.Sc., Ph.D., is an accomplished researcher and educator specializing in cancer biology, nanotechnology, and advanced 3D cell culture models. Currently serving as an Assistant Professor at the Department of Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai since February 2025, she previously worked as a guest lecturer at Tamil Nadu Veterinary and Animal Sciences University, College of Food and Dairy Technology, from April 2024 to January 2025. Dr. Baskar completed her Ph.D. in Biotechnology from Dr. M.G.R. Educational and Research Institute in 2025, where her dissertation focused on the development of breast cancer patient-derived organoids for personalized drug screening using targeted protein and genetic biomarkers and nanotherapeutics. She holds an M.Sc. in Biotechnology from Dwaraka Doss Vaishnav College (2020) and a B.Sc. in Biotechnology from Dr. M.G.R. Educational and Research Institute (2018). Her research interests include the green synthesis of metal nanoparticles from marine algae, antioxidant and anticancer activities of nanoparticles, patient-derived organoid development, biomarker-based cancer diagnostics, microfluidics, lab-on-a-chip technologies, and elucidating molecular mechanisms in cancer progression such as EMT, AKT/PI3K, and ferroptosis pathways. She is skilled in 2D and 3D cell culture, molecular and microbial techniques, nanoparticle synthesis, and preclinical diagnostic platforms. Dr. Baskar has contributed to over 18 Scopus-indexed publications in high-impact journals covering nanotherapeutics, cancer biosensors, ferroptosis, and targeted therapy approaches. She has also completed internships in food and water quality analysis and analytical techniques, and possesses strong communication, leadership, and time-management skills alongside a diploma in computer applications. Recognized for her hard work and innovative research, she continues to advance cancer therapeutics and diagnostics through translational and interdisciplinary approaches, aiming to bridge nanotechnology, molecular biology, and clinical applications for personalized medicine.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate

Featured Publications

  • Viswanathan, S., Palaniyandi, T., Kannaki, P., Shanmugam, R., Baskar, G., et al. (2023). Biogenic synthesis of gold nanoparticles using red seaweed Champia parvula and its anti-oxidant and anticarcinogenic activity on lung cancer. Particulate Science and Technology, 41(2), 241–249. Cited by 114

  • Viswanathan, S., Palaniyandi, T., Shanmugam, R., Karunakaran, S., Pandi, M., et al. (2024). Synthesis, characterization, cytotoxicity, and antimicrobial studies of green synthesized silver nanoparticles using red seaweed Champia parvula. Biomass Conversion and Biorefinery, 14(6), 7387–7400. Cited by 51

  • Palaniyandi, T., Baskar, G., B. V., Viswanathan, S., Abdul Wahab, M. R., et al. (2023). Biosynthesis of iron nanoparticles using brown algae Spatoglossum asperum and its antioxidant and anticancer activities through in vitro and in silico studies. Particulate Science and Technology, 41(7), 916–929. Cited by 28

  • Wahab, M. R. A., Palaniyandi, T., Viswanathan, S., Baskar, G., Surendran, H., et al. (2024). Biomarker-specific biosensors revolutionise breast cancer diagnosis. Clinica Chimica Acta, 555, 117792. Cited by 27

  • Prabhakaran, P., Palaniyandi, T., Kanagavalli, B., Hari, R., Sandhiya, V., et al. (2022). Prospect and retrospect of 3D bio-printing. Acta Histochemica, 124(7), 151932. Cited by 25

 

Vivek Kumar Garg | Breast Cancer | Best Researcher Award

Published on by NESIN Awards

Assoc. Prof. Dr. Vivek Kumar Garg | Breast Cancer | Best Researcher Award

Associate Professor | Rayat-Bahra University | India  

Assoc. Prof. Dr. Vivek Kumar Garg is an accomplished academic and researcher in the field of neurology and medical biochemistry, currently serving as Associate Professor at Rayat Bahra University, Mohali, with prior academic and research appointments at Chandigarh University, PGIMER Chandigarh, and the Institute of Genomics and Integrative Biology, New Delhi. He earned his Ph.D. in Neurology from PGIMER, Chandigarh, in 2018, focusing on the pharmacogenetics of antiepileptic drug-related adverse reactions in the North Indian population, following his M.Sc. in Medical Biochemistry (2008) and B.Sc. in Human Anatomy, Physiology, and Biochemistry (2006) from BFUHS, Faridkot. His professional experience spans teaching, research, and clinical diagnostics, including roles as Research Scientist in the COVID-19 laboratory at Punjab Biotechnology Incubator and as Demonstrator in Biochemistry at Government Medical College and Hospital, Chandigarh. His research interests include pharmacogenomics, neurodegenerative disorders, drug-induced adverse reactions, and biomarker discovery for complex diseases such as epilepsy, Alzheimer’s disease, and cancer. He is skilled in advanced research methodologies, including PCR, real-time PCR, ELISA, auto-analyzers, flame photometry, and biostatistical analysis, with strong expertise in both laboratory techniques and clinical research design. Dr. Garg has published extensively in peer-reviewed and indexed journals such as Human Immunology and Asian Journal of Psychiatry, and has also served as guest editor and editorial board member for international journals. He has guided multiple M.Sc. dissertations, delivered lectures, conducted workshops, and contributed as an examiner, BOS member, and research coordinator, reflecting his leadership in academia. His awards and honors include the prestigious ICMR Junior Research Fellowship, National Education Excellence Achievers Award, and multiple institutional recognitions as a transformative researcher and research luminary. With 1,757 citations, 90 documents, and an h-index of 18, Dr. Garg has established a strong academic footprint, reflecting both the impact of his research and his growing influence in biomedical sciences.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

  1. Kashyap, D., Garg, V. K., & Goel, N. (2021). Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis. Advances in Protein Chemistry and Structural Biology, 125, 73–120. Cited by: 411

  2. Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., … & Garg, V. K. (2021). Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Seminars in Cancer Biology, 69, 5–23. Cited by: 405

  3. Kashyap, D., Garg, V. K., Tuli, H. S., Yerer, M. B., Sak, K., Sharma, A. K., Kumar, M., … (2019). Fisetin and quercetin: Promising flavonoids with chemopreventive potential. Biomolecules, 9(5), 174. Cited by: 257

  4. Kashyap, D., Sharma, A., Tuli, H. S., Sak, K., Garg, V. K., Buttar, H. S., Setzer, W. N., … (2018). Apigenin: A natural bioactive flavone-type molecule with promising therapeutic function. Journal of Functional Foods, 48, 457–471. Cited by: 134

  5. Aggarwal, V., Kashyap, D., Sak, K., Tuli, H. S., Jain, A., Chaudhary, A., Garg, V. K., … (2019). Molecular mechanisms of action of tocotrienols in cancer: Recent trends and advancements. International Journal of Molecular Sciences, 20(3), 656. Cited by: 123

Boya Guan | Medical Oncology | Best Researcher Award

Published on by NESIN Awards

Prof. Boya Guan | Medical Oncology | Best Researcher Award

Pharmacist-in-charge​ at Tianjin Hospital | China

Boya Guan is a dedicated researcher and clinical pharmacist whose work bridges pharmacology, toxicology, and pharmaceutical sciences with a primary focus on osteosarcoma and bone cancer therapeutics. Over the course of her professional career, she has contributed significantly to oncology research by exploring drug mechanisms, drug resistance pathways, biomarker discovery, and clinical pharmacology applications. Her studies on triptolide-mediated ferroptosis and therapeutic strategies for overcoming drug resistance highlight her innovative approach to cancer research. Alongside her academic and clinical roles, she has been actively involved in translational projects that connect laboratory findings with patient care, ensuring that scientific discoveries lead to tangible clinical benefits. She has published in SCI-indexed journals, contributed to book chapters, and presented at national and international conferences, reflecting both the quality and impact of her work. With a strong commitment to research, innovation, and knowledge dissemination, she continues to shape advancements in oncology and pharmaceutical sciences.

Professional Profiles

Scopus Profile | ORCID Profile 

Education

Boya Guan has built a solid academic foundation that supports her extensive contributions to pharmaceutical research and clinical practice. She first pursued a degree in Pharmacy at Tianjin Medical University, where she developed a deep understanding of pharmacological principles and clinical applications. To expand her academic and professional horizons, she later completed a master’s program in Project and Operations Management at Southern New Hampshire University in the United States, equipping her with essential skills in management, leadership, and Six Sigma quality processes. This unique blend of pharmaceutical knowledge and operations management enabled her to approach research with a strategic and interdisciplinary perspective. She is currently advancing her expertise further by pursuing a master’s program in Pharmaceutical Analysis at Tianjin Medical University, focusing on advanced analytical methods and their role in clinical pharmacology. Her continuous academic development reflects her commitment to lifelong learning, professional growth, and scientific excellence in pharmaceutical sciences.

Experience

With over fourteen years of professional experience, Boya Guan has established herself as a highly skilled clinical pharmacist and researcher at Tianjin Hospital. In her role, she has been actively engaged in oncology-related pharmaceutical care, focusing on the mechanisms and efficacy of anticancer drugs while contributing to translational medicine initiatives. She has participated in significant clinical pharmacist training programs under the Tianjin Shortage Talent Program, where she deepened her expertise in oncology pharmacology and inpatient pharmaceutical care. Her experience is not limited to direct patient support; she has also been actively involved in clinical research, collaborating on projects that evaluate novel therapeutics such as denosumab for bone metastases and AI-based diagnostic tools. Beyond hospital-based responsibilities, she has presented her findings at conferences, published in peer-reviewed journals, and contributed book chapters, thereby extending her influence to both clinical and academic communities. Her experience reflects a balanced integration of research, practice, and innovation.

Research Interest

Boya Guan’s research interests lie at the intersection of oncology pharmacology, drug resistance mechanisms, and biomarker discovery, with a special focus on osteosarcoma therapeutics. She is particularly interested in investigating how targeted therapies and novel molecular pathways can overcome resistance to conventional drugs, thereby improving treatment outcomes for cancer patients. Her notable work includes exploring the role of triptolide in reversing cisplatin resistance through ferroptosis and lysosomal regulation, offering a promising therapeutic strategy. In addition to oncology, she is deeply engaged in analytical chemistry, employing dual-channel metabolomics and lipidomics approaches to identify biomarkers for diseases such as diabetes, thus contributing to early detection and precision medicine. She has also conducted systematic reviews and meta-analyses on VEGFR-TKIs in osteosarcoma, providing valuable evidence for clinical practice. Through her interdisciplinary approach, she aims to bridge pharmacology, translational research, and clinical application, ensuring her research has a meaningful and lasting impact on patient care.

Awards and Honors

Throughout her career, Boya Guan has earned recognition for her contributions to clinical pharmacy, research excellence, and innovative approaches to oncology therapeutics. She has been selected for prestigious programs such as the Tianjin Shortage Talent Program, which provided advanced clinical pharmacist training in oncology and inpatient care, underscoring her recognition as a promising specialist in pharmaceutical sciences. Her scientific contributions, including SCI-indexed journal publications, systematic reviews, and a book chapter on spinal metastases surgery, have also positioned her as a valuable contributor to academic and clinical communities. In addition to her professional achievements, she has been invited to present at multiple national and international conferences, where her research has been well received and acknowledged by peers. These honors reflect not only her strong academic and research background but also her potential to influence future directions in oncology and pharmaceutical research. Her growing recognition continues to strengthen her professional standing globally.

Research Skills

Boya Guan possesses a diverse range of research skills that combine laboratory expertise, clinical insight, and analytical methodologies. She is proficient in oncology pharmacology research, with specialized experience in studying drug resistance pathways, including ferroptosis-related mechanisms in osteosarcoma. Her analytical chemistry expertise includes metabolomics and lipidomics approaches for biomarker discovery, enabling her to contribute to the development of diagnostic and prognostic tools for complex diseases. She is skilled in conducting systematic reviews, meta-analyses, and clinical evaluations, ensuring evidence-based contributions to both research and practice. Additionally, she has demonstrated competence in designing and managing multidisciplinary research projects, including collaborations on AI-based diagnostic systems and drug efficacy studies. Her ability to translate laboratory findings into clinical strategies highlights her strength in bridging basic science with medical application. Coupled with strong writing, publication, and presentation skills, she is well-equipped to advance knowledge dissemination and foster innovation in oncology and pharmaceutical sciences.

Publication Top Notes

Title: Development of a dual-channel analytical approach for diabetic biomarker discovery in blood via integrative metabolomics and lipidomics
Year: 2025

Conclusion

Overall, Boya Guan is a highly deserving candidate for the Best Researcher Award. Her impactful contributions to osteosarcoma research, oncology pharmacology, biomarker discovery, and clinical drug evaluation showcase her ability to merge scientific innovation with real-world medical application. Her strong academic background, leadership in research, and commitment to improving cancer therapeutics reflect excellence in both scholarship and societal impact. With her continued focus on translational medicine and international collaborations, she holds significant potential to emerge as a global leader in oncology and pharmaceutical sciences.

Praveen Neeli | Oncology | Best Researcher Award

Published on by NESIN Awards

Dr. Praveen Neeli | Oncology | Best Researcher Award

Research Scientist at Moffitt Cancer Center | United States

Dr. Praveen Kumar Neeli is a passionate and innovative researcher in the fields of cancer biology, immunotherapy, and vaccine development. His research focuses on advancing therapeutic strategies such as CAR-T cell therapies, DNA-based vaccines, and immune checkpoint targeting for cancer and autoimmune diseases. Currently positioned at UT MD Anderson Cancer Center, he contributes to high-impact projects that bridge laboratory research with clinical applications, thereby influencing the future of oncology treatments. He has published extensively in top-tier journals, authored review articles, and contributed book chapters that highlight his deep scientific expertise. His patents and collaborations with industry underscore his ability to translate research findings into practical medical solutions. With over 520 citations and a growing h-index, Dr. Neeli’s work demonstrates significant scientific impact. He also holds editorial and reviewer roles in several reputed journals, further establishing his leadership and commitment to the global research community.

Professional Profiles

Google Scholar | Scopus Profile | ORCID Profile 

Education

Dr. Neeli holds a Ph.D. in Applied Biology with a specialization in cancer biology from the CSIR-Indian Institute of Chemical Technology, where he explored the molecular mechanisms of breast cancer progression by studying metadherin splice variants. His doctoral research laid the foundation for his later interest in cancer therapeutics. Prior to his Ph.D., he completed a Master’s degree in Genetics and a Bachelor’s degree in Biotechnology, Biochemistry, and Chemistry from Osmania University, which gave him strong grounding in biological sciences and laboratory practices. To complement his scientific expertise, he also pursued a Postgraduate Diploma in Patent Law from NALSAR University, which provides him a valuable perspective on intellectual property rights and translational research. This combination of academic credentials showcases both depth and breadth, reflecting a balance between advanced molecular biology and broader interdisciplinary skills, enabling him to contribute effectively to cutting-edge research and innovation in cancer biology and immunotherapy.

Experience

Dr. Neeli has built extensive research experience through progressive roles in prestigious institutions across India and the United States. At UT MD Anderson Cancer Center, he works as a postdoctoral fellow developing CAR-T therapies to address both cancer and autoimmune diseases, a project with transformative clinical potential. Prior to this, at Baylor College of Medicine, he was involved in designing DNA-based vaccines targeting cancers and infectious diseases, further strengthening his expertise in immunology and molecular therapeutics. Earlier in his career, he contributed to projects at CSIR-Centre for Cellular and Molecular Biology and Osmania University, focusing on molecular biology techniques such as cloning, expression, and purification of proteins. These experiences have enabled him to develop mastery in molecular biology, cell biology, immunological assays, and translational cancer research. Additionally, his editorial and reviewer roles, mentorship of students, and participation in international conferences demonstrate both his leadership and active engagement in the research community.

Research Interest

Dr. Neeli’s primary research interests lie in the development of innovative cancer immunotherapies and vaccines that can translate into effective clinical solutions. His current focus is on CAR-T cell therapies, aiming to engineer immune cells to specifically target cancer and autoimmune disease mechanisms. He is equally passionate about DNA-based vaccines and antibody engineering, particularly for their potential to treat hematological malignancies, breast cancer, and solid tumors. His work bridges molecular biology, immunology, and translational medicine, reflecting a comprehensive approach to therapeutic innovation. Additionally, he is interested in understanding tumor microenvironments, immune modulation, and mechanisms of drug resistance in cancer progression. The intersection of basic science and clinical application excites him, as it allows for the creation of therapies that directly benefit patients. He is also keen on exploring collaborative, multidisciplinary projects that integrate molecular biology with bioinformatics and clinical oncology to address unmet medical needs in cancer treatment.

Awards and Honors

Throughout his career, Dr. Neeli has been recognized with numerous awards and fellowships that highlight his academic and research excellence. He was awarded the ICMR Doctoral Research Fellowship, a highly competitive fellowship in India, which supported his Ph.D. work on breast cancer biology. His outstanding performance in national-level examinations such as GATE, CSIR-NET, and AP-SET further reflect his strong academic foundation and scientific aptitude. He has also actively participated in prestigious conferences including the American Association of Cancer Research (AACR) Annual Meeting, International Chemical Biology Society (ICBS), and other global research forums, showcasing his work to international audiences. His recognition extends beyond research fellowships to patents and technology development, with compounds licensed to pharmaceutical industries, which demonstrates the translational value of his contributions. These awards and achievements reflect not only his scientific excellence but also his commitment to bridging fundamental research with clinical and industrial applications.

Research Skills

Dr. Neeli possesses a diverse and advanced set of research skills spanning molecular biology, cell biology, immunology, and translational oncology. He is highly skilled in techniques such as cloning, gene expression, protein purification, site-directed mutagenesis, and chromatin immunoprecipitation. His expertise extends to advanced immunological methods, including ELISA, ELISPOT, flow cytometry, immune cell sorting, co-culture assays, and CAR-T cell engineering. He has significant experience in mammalian cell culture, confocal microscopy, and live imaging, as well as handling small animal models for preclinical studies. His work also involves bioinformatics tools for scientific analysis and visualization, combined with strong skills in scientific writing and communication. Additionally, his patents and translational projects highlight his capacity to move from bench research to industry-level applications. These skills collectively position him as a versatile and impactful researcher, capable of addressing complex biomedical challenges and contributing meaningfully to the advancement of cancer immunotherapy and vaccine development.

Publication Top Notes

Title: Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunction
Authors: S. Karnewar, P.K. Neeli, D. Panuganti, S. Kotagiri, S. Mallappa, N. Jain, et al.
Year: 2018
Citation: 147

Title: The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects
Authors: B. Lu, J.M. Lim, B. Yu, S. Song, P. Neeli, N. Sobhani, P.K., S.R. Bonam, et al.
Year: 2024
Citation: 95

Title: Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Authors: N. Sobhani, B. Scaggiante, R. Morris, D. Chai, M. Catalano, D.R. Tardiel-Cyril, P. Neeli, et al.
Year: 2022
Citation: 77

Title: AR-V7 in metastatic prostate cancer: a strategy beyond redemption
Authors: N. Sobhani, P.K. Neeli, A. D’Angelo, M. Pittacolo, M. Sirico, I.C. Galli, et al.
Year: 2021
Citation: 64

Title: AMPK inhibits MTDH expression via GSK 3β and SIRT 1 activation: potential role in triple negative breast cancer cell proliferation
Authors: P.N. Gollavilli, A.K. Kanugula, R. Koyyada, S. Karnewar, P.K. Neeli, et al.
Year: 2015
Citation: 59

Title: A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFĸB-SIRT3 axis
Authors: P.K. Neeli, P.N. Gollavilli, S. Mallappa, S.G. Hari, S. Kotamraju
Year: 2020
Citation: 41

Title: Mitochondria-targeted esculetin mitigates atherosclerosis in the setting of aging via the modulation of SIRT1-mediated vascular cell senescence and mitochondrial function
Authors: S. Karnewar, S. Pulipaka, S. Katta, D. Panuganti, P.K. Neeli, R. Thennati, et al.
Year: 2022
Citation: 37

Title: Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization
Authors: S. Mallappa, P.K. Neeli, S. Karnewar, S. Kotamraju
Year: 2019
Citation: 35

Title: Expanding anti-CD38 immunotherapy for lymphoid malignancies
Authors: M.Z.Y.L., X. Wang, X. Yu, W. Li, P. Neeli, M. Liu, L. Li
Year: 2022
Citation: 31

Title: p53 antibodies as a diagnostic marker for cancer: A meta-analysis
Authors: N. Sobhani, G. Roviello, A. D’Angelo, R. Roudi, P.K. Neeli, D. Generali
Year: 2021
Citation: 22

Title: DOT1L regulates MTDH mediated angiogenesis in triple-negative breast cancer: Intermediacy of NF-κB-HIF1α axis
Authors: P.K. Neeli, S. Sahoo, S. Karnewar, G. Singuru, S. Pulipaka, S. Annamaneni, et al.
Year: 2022
Citation: 16

Title: AI-powered discovery of a novel p53-Y220C reactivator
Authors: Y. Li, S. Zhou, D. Chai, X. Wang, P. Neeli, X. Yu, A. Davtyan, K. Young
Year: 2023
Citation: 11

Conclusion

Dr. Praveen Kumar Neeli is a highly deserving candidate for the Best Researcher Award. His cutting-edge research in CAR-T therapies, DNA vaccines, and cancer biology demonstrates both scientific depth and translational impact. With multiple high-impact publications, patents, international collaborations, and community contributions, he stands out as a researcher who not only advances knowledge but also contributes meaningfully to clinical applications and society. His growing leadership roles, strong academic foundation, and ongoing projects position him as a promising future leader in oncology and immunotherapy research.

Neha Akkad | Oncology | Best Researcher Award

Published on by NESIN Awards

Dr. Neha Akkad | Oncology | Best Researcher Award

Hematology and oncology Fellow, MD Anderson Cancer Center, United States

Dr. Neha Akkad is a highly deserving candidate for the Best Researcher Award. Her research contributions have significantly advanced the understanding of cancer biology, particularly in pancreatic cancer and lymphoma. She has made exceptional strides in immune-oncology, especially through her work on macrophage signaling and immune suppression mechanisms in the tumor microenvironment. Additionally, her published work is highly regarded by peers and is contributing to the global discourse on cancer research.

Professional Profile

Education🎓

Neha Akkad has pursued a rigorous and comprehensive academic journey in the medical field. She completed her undergraduate studies with a strong foundation in the biological sciences, which laid the groundwork for her medical education. She earned her Doctor of Medicine (MD) degree from a reputable institution, where she demonstrated excellence in both clinical and academic performance. Her education has been marked by a consistent commitment to medical knowledge, research, and patient care.

Professional Experience📝

Dr. Akkad has been involved in several research projects, focusing on areas relevant to her clinical specialty. Her research has included both clinical trials and retrospective studies, often aimed at improving patient outcomes or understanding disease mechanisms. She has collaborated with interdisciplinary teams and contributed to study design, data analysis, and manuscript preparation, showcasing her analytical and investigative skills.

Research Interest🔎

Dr. Neha Akkad’s research interests lie at the intersection of clinical practice, medical innovation, and healthcare outcomes. She is particularly focused on investigating evidence-based strategies to improve patient care, clinical decision-making, and healthcare delivery. Her work often explores topics such as [insert specific topics, e.g., cardiovascular risk assessment, health disparities, patient-reported outcomes, or quality improvement initiatives, depending on her specialty].

Award and Honor🏆

Throughout her career, Dr. Akkad has received numerous accolades recognizing her academic achievements, clinical excellence, and leadership. These honors reflect her exceptional work ethic, compassion in patient care, and contributions to her field. She has been acknowledged by both peers and mentors for her professionalism and dedication.

Research Skill🔬

Dr. Neha Akkad possesses a diverse and well-rounded skill set that spans clinical medicine, medical education, and research. Clinically, she is adept in patient assessment, diagnosis, and management across a wide range of conditions, with particular expertise in [insert specialty if known, e.g., internal medicine, cardiology, etc.]. She demonstrates proficiency in performing procedures relevant to her field and maintains a strong focus on evidence-based care and patient safety.

Conclusion💡

Dr. Akkad’s research is a clear reflection of her passion for advancing cancer therapeutics and her ability to bridge the gap between basic research and clinical application. While there are minor areas for improvement, her achievements in the field of oncology make her an excellent candidate for the Best Researcher Award. Her work has the potential to bring transformative changes to cancer treatment strategies, solidifying her as one of the leading researchers in her field.

Publications Top Noted✍️

Title: Evaluation of Breast Implant–Associated Anaplastic Large Cell Lymphoma With Whole Exome and Genome Sequencing.
Authors: Akkad N, Kodgule R, Duncavage EJ, et al.
Year: 2023
Journal: Aesthetic Surgery Journal.

Title: γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation.
Authors: Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, et al.
Year: 2016
Journal: Cell.

Title: NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma.
Authors: Daley D, Mani VR, Mohan N, Akkad N, et al.
Year: 2017
Journal: Journal of Experimental Medicine.

Title: Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.
Authors: Daley D, Mani VR, Mohan N, Akkad N, Ochi A, et al.
Year: 2017
Journal: Nature Medicine.

Title: Pola-R-CHP: a dramatic shift in the frontline treatment paradigm for diffuse large B-cell lymphoma, or a small step forward?
Authors: Akkad N, Nastoupil LJ.
Year: 2024
Journal: The Hematologist.

Title: Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients.
Authors: Petrosyants A, Wiebe D, Nze C, Akkad N, et al.
Year: 2024
Journal: Blood.